Prostate Cancer Radiation Comparisons Support IMRT, Question Proton Therapy
This article was originally published in The Gray Sheet
Executive Summary
A large Medicare database analysis provides support for intensity-modulated radiation therapy as the standard radiation tool for prostate cancer, while the nascent proton therapy showed no advantages.
You may also be interested in...
News Briefs: 23andMe’s Mea Culpa; FDA Reaches Settlement With J&J; Meaningful Use Delay
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.
ProNova Preps Its Next-Gen SC360 For Smaller, Cheaper Era Of Proton Therapy
The system, which developers hope to launch in the U.S. in 2015 following completion of a 510(k) submission to FDA, will cost about $50 million for a two-room configuration, and the gantry will weigh 15 tons, well under the typical 110-220-ton weight of most systems, according to ProNova.
ASTRO Meeting In Brief
Research and product news from the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting, held Oct. 28-31 in Boston